IP Library Granted Patent US 12,133,884
Granted Patent B2
US 12,133,884 · App. 17/054,424 · Granted Nov 5, 2024

Methods of substituting pathogenic amino acids using programmable base editor systems

Inventors: David Bryson (Cambridge, MA); John Evans (Cambridge, MA); Michael Packer (Cambridge, MA); Yanfang Fu (Cambridge, MA); Nicole Gaudelli (Cambridge, MA); Jason Michael Gehrke (Cambridge, MA); J. Keith Joung (Cambridge, MA)
Assignee: Beam Therapeutics Inc.
A61K38/50A61K31/7088A61K38/465C12N9/22C12N9/78C12N15/102C12N15/11C12N15/907C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,133,884
App. No.
17/054,424
Granted
Nov 5, 2024
Kind
B2
Abstract

Provided herein are compositions and methods of using base editors comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide. Also provided herein are base editor systems for editing nucleobases of target nucleotide sequences.

Claims (9)

1. A method of editing a β-globin (HBB) polynucleotide comprising a single nucleotide polymorphism (SNP) associated with sickle cell disease, wherein the SNP associated with sickle cell disease results in expression of an HBB polypeptide having a valine at amino acid position 7 of SEO ID NO: 37, the method comprising contacting the HBB polynucleotide with a base editor in complex with one or more single guide RNAs (sgRNAs), wherein the base editor comprises a Streptococcus pyogenes Cas9 polynucleotide programmable DNA binding domain having specificity for a protospacer-adjacent motif comprising the nucleic acid sequence 5′-NGC-3′ and an adenosine deaminase domain, wherein the one or more guide polynucleotides target the base editor to effect an A•T to G•C alteration of the SNP associated with sickle cell disease, thereby substituting an alanine for the valine at amino acid position 7 referenced to SEO ID NO: 37, wherein the first and the last three bases of the one or more sgRNAs are phosphorothioate and 2′-O-methyl modified, and wherein the one or more sgRNAs comprise a spacer complementary to an HBB nucleic acid sequence corresponding to the target sequence ACTTCTCCACAGGAGTCAGA (positions 1-20 of SEO ID NO: 251) and adjacent to a protospacer-adjacent motif comprising the nucleic acid sequence 5′-NGC-3′.

2. The method of claim 1 , wherein the polynucleotide programmable DNA binding domain is a nuclease inactive or nickase variant.

3. The method of claim 2 , wherein the nickase variant comprises a D10A amino acid substitution referenced to SEO ID NO: 47.

4. The method of claim 1 , wherein the adenosine deaminase comprises an amino acid sequence having at least 85% identity to the following amino acid sequence:

SEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWNRPIG

RHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRI

GRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDF

FRMRRQEIKAQKKAQSSTD (positions 2-167 of SEQ ID NO: 

151).

Assignments (3)
SECURITY INTEREST Recorded Mar 6, 2026
From: BEAM THERAPEUTICS INC.
To: SIXTH STREET LENDING PARTNERS, AS ADMINISTRATIVE AGENT
Reel/Frame 075021/0929 →
SECURITY INTEREST Recorded Feb 24, 2026
From: BEAM THERAPEUTICS INC.; GUIDE THERAPEUTICS, LLC; BBBR, LLC
To: SIXTH STREET LENDING PARTNERS, AS ADMINISTRATIVE AGENT
Reel/Frame 074955/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2021
From: BRYSON, DAVID; EVANS, JOHN; PACKER, MICHAEL; FU, YANFANG; GAUDELLI, NICOLE; GEHRKE, JASON MICHAEL; JOUNG, J. KEITH
To: BEAM THERAPEUTICS INC.
Reel/Frame 054845/0168 →
Continuity (4)
Provisional Application 62780890 · Dec 17, 2018
Provisional Application 62670539 · May 11, 2018
Provisional Application 62670521 · May 11, 2018
Related Publication 20220401530A1 · Dec 22, 2022
Cited By (1)
US 12,644,123